

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Opus Genetics, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

67577R102

(CUSIP Number)

05/12/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP 67577R102
Number(s):

1	Names of Reporting Persons AARON G.L. FLETCHER
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization

	UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.53 %	
12	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Management is a general partner of Bios Equity III. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

CUSIP Number(s): 67577R102

1	Names of Reporting Persons BIOS ADVISORS GP, LLC	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power

	3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>
11	Percent of class represented by amount in row (9) 4.53 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Management is a general partner of Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

CUSIP Number(s): 67577R102

1	Names of Reporting Persons BIOS CAPITAL MANAGEMENT, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.53 %	
12	Type of Reporting Person (See Instructions)	

Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity III and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

CUSIP Number(s): 67577R102

1	Names of Reporting Persons BIOS EQUITY PARTNERS III, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.53 %	
12	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds (defined below). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of each of Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT") (collectively, the "Bios III Funds"), and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

CUSIP 67577R102
Number(s):

1	Names of Reporting Persons BIOS FUND III, LP
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 0.00
	6 Shared Voting Power 430,665.00
	7 Sole Dispositive Power 0.00
	8 Shared Dispositive Power 430,665.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 430,665.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>
11	Percent of class represented by amount in row (9) 0.53 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

CUSIP 67577R102
Number(s):

1	Names of Reporting Persons BIOS FUND III NT, LP
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 450,811.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 450,811.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 450,811.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 0.55 %	
12	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

CUSIP Number(s):	67577R102
------------------	-----------

1	Names of Reporting Persons BIOS FUND III QP, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,801,953.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,801,953.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,801,953.00	

10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>
11	Percent of class represented by amount in row (9) 3.44 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

CUSIP Number(s):	67577R102
-------------------------	-----------

1	Names of Reporting Persons CAVU ADVISORS, LLC	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.53 %	
12	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management is a general partner of Bios Equity III. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

CUSIP Number(s): 67577R102

1	Names of Reporting Persons CAVU MANAGEMENT, LP	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.53 %	
12	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity III and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

CUSIP Number(s): 67577R102

1	Names of Reporting Persons LESLIE W. KREIS
---	---

2	Check the appropriate box if a member of a Group (see instructions)	
	<input type="checkbox"/> (a)	
	<input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,683,429.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,683,429.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,683,429.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.53 %	
12	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management is a general partner of Bios Equity III. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13G

Item 1.

(a) **Name of issuer:**

Opus Genetics, Inc.

(b) **Address of issuer's principal executive offices:**

8 DAVIS DRIVE, SUITE 220, DURHAM, NORTH CAROLINA, 27713

Item 2.

(a) **Name of person filing:**

This Schedule 13G is being jointly filed by: Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Equity III, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors, Mr. Kreis, and Dr. Fletcher.

(b) **Address or principal business office or, if none, residence:**

1751 River Run #400 Fort Worth, TX 76107

(c) **Citizenship:**

Item 2(A) is incorporated herein by reference.

(d) **Title of class of securities:**

Common Stock, \$0.0001 par value per share

(e) CUSIP No.:

67577R102

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.

(b) Percent of class:

The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.

(ii) Shared power to vote or to direct the vote:

The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.

(iii) Sole power to dispose or to direct the disposition of:

The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.

(iv) Shared power to dispose or to direct the disposition of:

The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

The Related Persons of this Schedule 13G are hereby incorporated by reference into this Item 9.

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AARON G.L. FLETCHER

Signature: /s/ John Fucci
Name/Title: John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher
Date: 05/13/2026

BIOS ADVISORS GP, LLC

Signature: /s/ John Fucci
Name/Title: John Fucci/Attorney-in-Fact
Date: 05/13/2026

BIOS CAPITAL MANAGEMENT, LP

Signature: /s/ John Fucci
Name/Title: John Fucci/Attorney-in-Fact
Date: 05/13/2026

BIOS EQUITY PARTNERS III, LP

Signature: /s/ John Fucci
Name/Title: John Fucci/Attorney-in-Fact
Date: 05/13/2026

BIOS FUND III, LP

Signature: /s/ John Fucci
Name/Title: John Fucci/Attorney-in-Fact
Date: 05/13/2026

BIOS FUND III NT, LP

Signature: /s/ John Fucci
Name/Title: John Fucci/Attorney-in-Fact
Date: 05/13/2026

BIOS FUND III QP, LP

Signature: /s/ John Fucci
Name/Title: John Fucci/Attorney-in-Fact

Date: 05/13/2026

CAVU ADVISORS, LLC

Signature: /s/ John Fucci

Name/Title: John Fucci/Attorney-in-Fact

Date: 05/13/2026

CAVU MANAGEMENT, LP

Signature: /s/ John Fucci

Name/Title: John Fucci/Attorney-in-Fact

Date: 05/13/2026

LESLIE W. KREIS

Signature: /s/ John Fucci

Name/Title: John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr.

Date: 05/13/2026